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In view of the method of diagnosing sarcopenia being complex and considered to be difficult to
introduce into routine practice, the European Working Group on Sarcopenia in Older People
(EWGSOP) recommends the use of the SARC-F questionnaire as a way to introduce assess-
ment and treatment of sarcopenia into clinical practice. Only recently, some studies have
turned their attention to the presence of sarcopenia in systemic sclerosis (SSc).There is no
data about performance of SARC-F and other screening tests for sarcopenia in this population.
Objective
To compare the accuracy of SARC-F, SARC-CalF, SARC-F+EBM, and Ishii test as screen-
ing tools for sarcopenia in patients with SSc.
Methods
Cross-sectional study of 94 patients with SSc assessed by clinical and physical evaluation.
Sarcopenia was defined according to the revised 2019 EWGSOP diagnostic criteria (EWG-
SOP2) with assessments of dual-energy X-ray absorptiometry, handgrip strength, and short
physical performance battery (SPPB). As case finding tools, SARC-F, SARC-CalF, SARC-
F+EBM and Ishii test were applied, including data on calf circumference, body mass index,
limitations in strength, walking ability, rising from a chair, stair climbing, and self reported
number of falls in the last year. The screening tests were evaluated through receiver operat-
ing characteristic (ROC) curves. Standard measures of diagnostic accuracy were computed
using the EWGSOP2 criteria as the gold standard for diagnosis of sarcopenia.
Results
Sarcopenia was identified in 15 (15.9%) patients with SSc by the EWGSOP2 criteria. Area
under the ROC curve of SARC-F screening for sarcopenia was 0.588 (95% confidence
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interval (CI) 0.420–0.756, p = 0.283). The results of sensitivity, specificity, positive likelihood
ratio (+LR), negative likelihood ratio (-LR) and diagnostic Odds Ratio (DOR) with the EWG-
SOP2 criteria as the gold standard were 40.0% (95% CI, 19.8–64.2), 81.0% (95% CI, 71.0–
88.1), 2.11 (95% CI, 0.98–4.55), 0.74 (95% CI, 0.48–1.13) and 2.84 (95% CI, 0.88–9.22),
respectively. SARC-CalF and SARC-F+EBM showed better sensitivity (53.3%, 95% CI
30.1–75.2 and 60.0%, 95% CI 35.7–80.2, respectively) and specificity (84.8%, 95% CI
75.3–91.1 and 86.1%, 95% CI 76.8–92.0, respectively) compared with SARC-F. The best
sensitivity was obtained with the Ishii test (86.7%, 95% CI 62.1–96.3), at the expense of a
small loss of specificity (73.4%, 95% CI 62.7–81.9). Comparing the ROC curves, SARC-F
performed worse than SARC-CalF, SARC-F+EBM and Ishii test as a sarcopenia screening
tool in this population (AUCs 0.588 vs. 0.718, 0.832, and 0.862, respectively). Direct com-
parisons between tests revealed differences only between SARC-F and Ishii test for sensi-
tivity (p = 0.013) and AUC (p = 0.031).
Conclusion
SARC-CalF, SARC-F+EBM, and Ishii test performed better than SARC-F alone as screen-
ing tools for sarcopenia in patients with SSc. Considering diagnostic accuracy and feasibility
aspects, SARC-F+EBM seems to be the most suitable screening tool to be adopted in rou-
tine care of patients with SSc.
Introduction
Sarcopenia was originally defined as age-related loss of muscle mass [1]. Recently, the Euro-
pean Working Group on Sarcopenia in Older People (EWGSOP) has updated the operational
definition of sarcopenia as a progressive and generalized skeletal muscle disorder that is associ-
ated with adverse outcomes including physical disability and mortality [2]. In its 2019 revised
definition, EWGSOP2 uses low muscle strength as the primary parameter of sarcopenia and
the diagnosis is confirmed by the presence of low muscle quantity or quality [2]. In view of the
method of diagnosing sarcopenia being still complex and considered difficult to introduce into
routine practice, the EWGSOP2 advises the use of the SARC-F questionnaire as a means of
finding individuals with probable sarcopenia so as to carry out its assessment and provide
treatment in clinical practice [2].
The SARC-F is a symptom score based on 5 self-reported questions concerning strength,
ambulation, rising up from a chair, climbing up a set of stairs, and falls [3]. In longitudinal stud-
ies, it has been demonstrated to predict the adverse consequences associated with sarcopenia,
such as physical disability, hospitalization, and mortality [4]. Despite SARC-F being easy to con-
duct, inexpensive, and validated in different populations [5–9], its sensitivity is relatively low, as
confirmed in a recent meta-analysis [10]. To overcome this limitation, some authors have com-
bined use of the SARC-F with other features in order to optimize the diagnostic properties of this
screening tool (SARC-Calf combining calf circumference [7] and SARC-F+EBM adding age and
body mass [5]). In the same way, Ishii test was devised so as to estimate the probability of sarcope-
nia by using a score based on three variables—age, grip strength, and calf circumference [11].
Systemic sclerosis (SSc) is a rare multisystem autoimmune disease characterized by wide-
spread vasculopathy and progressive fibrosis of the skin and other internal organs such as
lungs, gastrointestinal tract, and kidneys [12]. As a systemic inflammatory condition, promi-
nently affecting patients’ physical function and nutrition, SSc may be considered a major risk
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factor for sarcopenia [13–17]. According to different definitions, sarcopenia has been diag-
nosed in nearly 20% of patients with SSc [14, 15, 18], which is similar to other rheumatic dis-
eases, such as psoriatic arthritis (20%), rheumatoid arthritis (20.8%), and ankylosing
spondylitis (22.7%) [19].
Considering that patients with SSc are particularly prone to develop severe clinical compli-
cations associated with comorbid sarcopenia, such as physical function decline and death, and
that there are several case-finding instruments available not yet validated for SSc, we aimed to
compare the sensitivity of SARC-F, SARC-CalF, SARC-F+EBM, and Ishii test as screening
tools for sarcopenia in patients with SSc. In addition, we aimed to estimate the other standard
measures of diagnostic accuracy and the area under the receiver operating characteristic
(ROC) curves as the measurements to describe the accuracy of each screening test.
Methods
Patients and study design
A total of 142 consecutive patients with SSc were evaluated between March and December
2019, in a cross-sectional study carried out on a convenience sample of patients diagnosed
with SSc followed up at a public university hospital. For an expected prevalence of sarcopenia
of 20% in a sample of 94 patients with SSc, we could estimate a power greater than 80% to find
a sensitivity ranging from 50% to 85% [8, 11, 20]. Additionally, a post hoc calculation retrieved
a power of 99% for sensitivity and 54% for specificity. A study flowchart is presented in S1 Fig.
All patients were Brazilian and the vast majority inhabitants of the urban area of Porto Ale-
gre, RS. A standardized and comprehensive research questionnaire was applied to each partici-
pant by the same researcher (VH). Disease duration was defined as time from the first non-
Raynaud’s symptom. Disease subtype was classified as follows: diffuse cutaneous SSc (involv-
ing trunk and acral skin), limited cutaneous SSc (restricted to extremities and/or face), or sine
scleroderma [12]. The severity of skin disease was evaluated by using the modified Rodnan
skin score [21]. Patients also completed the SARC-F questionnaire and data about calf circum-
ference, body mass index, and handgrip strength were collected. Inclusion criterion was the
fulfillment of either one of the two mostly used classification criteria for SSc: the ACR/EULAR
2013 classification criteria for SSc [22] and the LeRoy/Medsger 2001 classification criteria for
early SSc [23]. Out of the 94 participants, 2 were classified as early SSc patients according to
LeRoy/Medsger criteria and 92 were classified as SSc patients according to ACR/EULAR 2013
criteria. Exclusion criteria were: (1) the presence of any overlapping systemic autoimmune dis-
ease, (2) severe renal disease, defined as a glomerular filtration rate less than 30ml/min/
1.73m2, (3) any liver disease, defined as an elevation of aspartate aminotransferase or alanine
aminotransferase above three times the upper limit of normal, (4) any chronic infection (e.g.,
hepatitis C virus, hepatitis B virus, human immunodeficiency virus), (5) severe chronic
obstructive pulmonary disease, defined as forced expiratory volume in one second less than
50% of the predicted value, (6) any concomitant malignancy, and (7) any inflammatory myop-
athy, defined as previous history of myopathy and/or an elevation of creatine phosphokinase
CPK or aldolase above 1.5 times the upper limit of normal. This study was conducted accord-
ing to the principles expressed in the Declaration of Helsinki, all patients signed written
informed consent and this research protocol was approved by the institutional Research Ethics
Committee of the Hospital de Clı́nicas de Porto Alegre/Brazil (CAAE 06473019.0.0000.5327).
Measurements
Body mass was measured with a calibrated digital scale, with participants standing barefoot
and wearing light clothes. Body height was measured with a standard fixed stadiometer. Body
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mass index (BMI) was calculated as weight (kg) per height (m2). Maximal calf circumference
was measured as the widest circumference of the right calf with the legs relaxed and feet 20 cm
apart from each other with an inextensible tape measure, according to the methods previously
described [24]. An anthropometric scale with a resolution of 100 g (Filizola S.A. Pesagem e
Automação, São Paulo, Brazil), a 1 mm precision stadiometer, and a 1 mm precision measur-
ing tape were used for these measurements.
Handgrip strength was measured using a handheld dynamometer (Jamar Hydraulic Hand
Dynamometer, Preston, USA) according to the methods proposed by Roberts et al [25].
Patients had to squeeze the device as hard as they could three times in each hand in an alternat-
ing manner, and the maximum strength was defined as the highest of the 6 values. Cut-off
points to define low strength were <27 kg for men and<16 kg for women according to the
EWGSOP2 [2].
The Short Physical Performance Battery (SPPB) was applied to evaluate physical perfor-
mance [26]. It consists of three separate tests: balance, 4 m gait speed and chair stand test. In the
balance test, the patient holds his balance for 10 seconds in three standing positions with eyes
open: feet side by side, feet in semi-tandem stance, and feet in tandem stance. Only one attempt
was permitted for each stance. In the gait speed test, patients walk a 4-m marked course at their
usual walking pace, with the examiner timing their walk with a stopwatch. Two attempts were
allowed on this test, with the fastest recorded time being used for the overall score. The chair
stand test examines the ability to rise from a sitting to a standing position from an armless
chair, with the arms folded across the chest. In the final part of the SPPB, a series of five conse-
cutive chair stands, which should be performed as quickly as possible. The examiner times the
patient’s performance with a stopwatch, counting aloud the number of stands completed. A
score between 0 and 4 was assigned for each component, reaching a maximum of 12 points.
According to the EWGSOP2, SPPB�8 defines low physical performance [2].
Body composition was measured by whole-body dual-energy X-ray absorptiometry (DXA)
(Lunar Prodigy Primo, GE Medical Systems, UK). Patients were wearing only underwear and
were asked to remove all metal accessories and jewelry before measurements, which were taken
in the morning. After that, patients were aligned in the center of the densitometer table with the
feet positioned together and with the hands positioned with palms flat against the densitometer
table (for larger subjects who do not fit within the constraints of the scanning field, hands were
placed laterally against the hips). Only one patient had knee prosthesis. Following the EWGOSP2
consensus recommendations to use lean soft tissue assessed by DXA to infer muscle mass quan-
tity [2], the appendicular skeletal muscle mass index (ASMI) was calculated as appendicular skel-
etal muscle mass (the sum of the muscle mass in both arms and legs) divided by height squared.
Considering the cut-off points recommended by the EWGSOP2, men with an ASMI below 7.0
kg/m2 and women below 5.5 kg/m2 were defined as presenting low muscle quantity.
Assessment of sarcopenia (EWGSOP2)
Sarcopenia was defined according to the 2019 revised EWGSOP2 criteria [2]. This definition
uses low muscle strength (determined by handgrip strength) as the primary parameter of sar-
copenia and the diagnosis is confirmed by the presence of low muscle mass (determined by
DXA). In the presence of low muscle strength, low muscle quantity and low physical perfor-
mance (determined by SPPB), sarcopenia is considered severe.
Sarcopenia screening tools
We used the SARC-F, SARC-CalF, SARC-F+EBM, and Ishii screening test to estimate the
presence of sarcopenia. The standard SARC-F is composed of 5 items questioning the strength,
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assistance in walking, rise from a chair, climb stairs, and self reported number of falls in the
last year (each one scored between 0 and 2) [3]. The score ranges from 0–10 and, in the origi-
nal study, a score equal to or greater than 4 was predictive of sarcopenia and poor outcomes
[3]. The original SARC-F questionnaire was already translated to Portuguese and validated as
a sarcopenia screening tool in Brazil with the optimal cut-off point equal to or greater than 6
[7]. In the current study, we applied this validated version; however, due to the lack of cut-offs
standardization, we performed separate analyses and chose the value with a better perfor-
mance in our specific sample which was equal to or greater than 4 (S1 File).
The SARC-CalF is composed of 6 items: the standard SARC-F (5 items: strength, walking
ability, rising from a chair, stair climbing, and self reported number of falls in the last year)
and a sixth additional item (maximal calf circumference) [7]. Calf circumference is measured
through scoring: zero representing the absence of low muscle mass (>34 cm for men and>33
cm for women) and 10 for presence (�34 cm for men and�33 cm for women). The score
ranges from 0–20. For the SARC-CalF, a total score of�11 indicates positive screening for sar-
copenia [7].
The SARC-F+EBM is a score that combines SARC-F with data about age and BMI [5]. For
age, patients with< 75 years of age scored zero point, whereas� 75 years of age scored 10
points. For BMI, patients not being underweight (>21 kg/m2) scored zero point, whereas
underweight (�21 kg/m2) patients scored 10 points. The score ranges from 0–30. For the
SARC-F+EBM, a total score of�12 indicates positive screening for sarcopenia [5].
The Ishii screening test calculates the probability of sarcopenia based on three selected vari-
ables: age, grip strength and calf circumference [11]. The formula to calculate the score is as
follows: score in men = 0.62 (age– 64)– 3.09 (grip strength– 50)– 4.64 (calf circumference–
42), score in women = 0.80 (age– 64)– 5.09 (grip strength– 34)– 3.28 (calf circumference– 42).
Alternatively, this score could be easily obtained from the values of the three variables com-
bined on a simple score chart in each sex. For the Ishii test, a total score of�105 in men and
�120 in women is suggestive of sarcopenia [11].
Statistical analysis
Statistical analyses were performed by using the Statistical Package for the Social Sciences ver-
sion 23.0 (SPSS Statistics; IBM, Armonk, NY) and MedCalc Statistical Software version 16.8.4
(MedCalc Software, Ostend, Belgium). Variables with a normal distribution were presented as
mean and standard deviation (SD), and non-normal quantitative variables were presented as
the median and interquartile range (IQR). Sensitivity, specificity, positive likelihood ratio
(+LR), negative likelihood ratio (-LR), positive predictive value (PPV), negative predictive
value (NPV), and diagnostic Odds Ratio (DOR) were computed by using the EWGSOP2 crite-
ria as the gold standard for diagnosis of sarcopenia. The diagnostic accuracy of the SARC-F,
SARC-CalF, SAR-F+EBM, and Ishii screening tests were calculated so as to identify sarcope-
nia. The overall accuracy of screening tests was evaluated by ROC curves. The area under the
ROC curve (AUC) and 95% confidence interval (CI) were calculated for all tests and Youden’s
J statistics was used to compare the performance of SARC-F with different cut-off values. An
AUC greater than 0.9 has high accuracy, whereas 0.7 and 0.9 indicate moderate accuracy, 0.5
and 0.7 low accuracy, and 0.5 a chance result [26]. To compare sensitivity, specificity, +LR,
-LR, PPV, NPV, and AUC of the screening tests, we used one-way ANOVA with Tukey HSD
("Honestly Significant Difference") post-hoc test to indicate which groups were significantly
different from others. There were no missing values of any variable in the entire analytic sam-
ple. All statistical tests were 2-sided. A p value of less than 0.05 was considered statistically
significant.
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Results
Out of 142 patients evaluated initially, 37 were excluded for not meeting inclusion criteria. Of
these 105 patients, 11 patients refused to participate, remaining a total of 94 patients diagnosed
with SSc (7 men and 87 women). The mean age mean age of the total sample was 60.5±10.3
years (range 33–79 years of age). Table 1 shows the clinical characteristics of patients with SSc
stratified by sex.
Sarcopenia was identified in 15 patients with SSc (15.9%) by the EWGSOP2 criteria (Fig 1)
and severe sarcopenia in 5 patients (5.3%). Average (SD) scores for screening tools were:
SARC-F 2.56 (1.84), SARC-CalF 5.12 (4.96), SARC-F+EBM 5.01 (5.12), Ishii test 96.31 (37.75).
Concerning the ability to evaluate sarcopenia, the ROC curves of the four screening tests
against the EWGSOP2 definition of sarcopenia are shown in Fig 2.
Table 2 presents the results of sensitivity/specificity analysis and AUC of these tests in the
whole study population by using EWGSOP2 diagnostic criteria as the reference standard. The
raw data of each tool vs. the gold standard diagnostic results were provided in 2x2 tables as S1
File. Area under the ROC curve of SARC-F screening for sarcopenia was 0.588 (95% CI 0.420–
0.756, p = 0.283). The SARC-F results of sensitivity, specificity, +LR, -LR, and DOR with the
EWGSOP2 criteria as the gold standard were 40.0% [95% CI, 19.8–64.2], 81.0% (95% CI, 71.0–
88.1), 2.11 (95% CI, 0.98–4.55), 0.74 (95% CI, 0.48–1.13) and 2.84 (95% CI, 0.88–9.22),
Table 1. Clinical characteristics of patients with SSc, stratified by sex.
Characteristics Women (n = 87) Men (n = 7)
Age (years)a 60.8 ±10.2 56 (23)
Caucasian 71 (81.6) 6 (85.7)
Smoking status
Never 48 (55.1) 2 (28.6)
Previous 31 (35.6) 4 (57.1)
Current 8 (9.2) 1 (14.3)
Diffuse skin involvement 17 (20) 3 (42.9)
Rodnan Skin Scorea 4 (8) 11 (9)
Disease durationa 12.8 (12.3) 9.1 (12.6)
Anthropometric measuresa
Weight (kg) 64.8 ±11.7 70.6 (6.8)
Height (cm) 158 ±6.2 174 (6)
BMI (kg/m2) 25.9 ±4.7 22.3 (6.7)
Calf circumference (cm) 35.8 ±3.7 35.2 (5.5)
Years of formal education
< 2 years 38 (43.7) 3 (42.9)
2–10 years 19 (21.8) 4 (57.1)
> 10 years 30 (34.5) 0 (0)
Handgrip strength (kg)a 18 (13) 26 (9)
SPPBb (points)a 10 (2) 10 (1)
Gait speed (m/s)a 1.09 ±0.33 1.07 (0.24)
ASMI (kg/m2)a 6.4 ±0.8 7.6 (1.2)
Data are presented as number (percentage) of patients, except when indicated otherwise.
a Data are presented as mean ±standard deviation or median (interquartile range).
b SPPB: 0–12 points being the score range.
Abbreviations: ASMI: appendicular skeletal muscle mass index; BMI: body mass Index; SPPB: short physical
performance battery; SSc: systemic sclerosis.
https://doi.org/10.1371/journal.pone.0245683.t001
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respectively. The optimal cut-off point of SARC-F in our sample was�4 (Youden index: 0.21),
the same cut-off point recommended in the literature [3, 10]. Only 6 (40%) out of the 15 par-
ticipants with sarcopenia were identified by the SARC-F questionnaire in our population.
However, the SARC-F properly identified 4 out of 5 patients who had severe sarcopenia.
As summarized in Table 2, the magnitude of the sensitivity could vary widely: from 40% for
the SARC-F alone to 86.7% for the Ishii screening test. SARC-CalF showed better sensitivity
(53.3%, 95% CI 30.1–75.2) and better specificity (84.8%, 95% CI 75.3–91.1) compared with
SARC-F. The same occurred with the SARC-F + EBM, that presented better sensitivity (60.0%,
95% CI 35.7–80.2) and also a slightly better specificity (86.1%, 95% CI 76.8–92.0) than
SARC-F alone and SARC-CalF. The best sensitivity (86.7%, 95% CI 62.1–96.3) and the best
NPV (96.7%, 95% CI 88.8–99.1) were obtained with the screening test of Ishii et al, at the
expense of a relatively small loss of specificity (73.4%, 95% CI 62.7–81.9). In contrast, the most
specific tool was the SARC-F+EBM (86.1%, 95% CI 76.8–92.0), which also presented de high-
est +LR (4.31, 95% CI 2.17–8.56) and PPV (45%, 95% CI 29.2–61.9).
Comparing the aforementioned ROC curves (Fig 2), SARC-F performed worse than the
SARC-CalF, SARC-F+EBM and Ishii test as a sarcopenia screening tool (AUCs 0.588 vs. 0.718,
0.832, and 0.862, respectively).
Additionally, when all tests were evaluated together, there were no differences among
screening tests for specificity (p = 0.156), PPV (p = 0.473), NPV (p = 0.077), +LR (p = 0.639)
and -LR (p = 0.098), whereas sensitivity (p = 0.020) and AUC (p = 0.026) were statistically dif-
ferent. Post-hoc direct comparisons between tests revealed differences only between SARC-F
and Ishii test for sensitivity (p = 0.013) and AUC (p = 0.031).
Discussion
An ideal screening test has to combine a reasonably high sensitivity to find cases in the tested
population with a relative high specificity to reduce the number of false positives, avoiding
unnecessary and expensive investigations [9, 27]. Aligned with results of previous reports, our
study demonstrated that SARC-F presents a poor sensitivity but a high specificity [3–5, 7–9].
Also, in a recent meta-analysis including 7 studies (12,800 subjects), the pooled results of
SARC-F sensitivity, specificity, and DOR with the EWGSOP first criteria as the gold standard
were 21% (95% CI, 13–31), 90% (95% CI, 83–94), and 2.47 (95% CI, 1.64–3.74), respectively
Fig 1. Prevalences of sarcopenia according to each screening tool and diagnostic gold standard (EWGSOP2).
https://doi.org/10.1371/journal.pone.0245683.g001
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(10). In our sample, 15.9% of patients with SSc had sarcopenia, according to the EWGSOP2
criteria (gold standard), and SARC-F sensitivity, specificity and DOR were 40% (95% CI, 19.8–
64.2), 81% (95% CI, 71.0–88.1) and 2.84 (95% CI, 0.88–9.22), respectively. Even though our
findings indicate a relatively greater sensitivity, it still lacks clinical utility as 60% of patients
with sarcopenia will test negative on SARC-F. The highest sensitivity was from Ishii test,
according to which 13.3% of patients with sarcopenia will test negative. A screening tool for
Fig 2. Receiver operating characteristic (ROC) curve analysis of four sarcopenia screening tests in relation to
sarcopenia defined according to EWGSOP2 criteria: SARC-F (A), SARC-CalF (B), SARC-F + EBM (C), and Ishii
screening test (D). Comparison of ROC curves between the SARC-F, SARC-CalF, SARC-F + EBM, and Ishii’s scores
for the sarcopenia screening (E).
https://doi.org/10.1371/journal.pone.0245683.g002
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sarcopenia presenting high sensitivity is important for prompt identification of patients at risk
in clinical practice, allowing to start at the earliest diagnostic confirmation and preventive
strategies [9].
On the other hand, the diagnostic accuracy of a screening tool also could be assessed using
the AUC value. According to this approach, the observed performance of SARC-F as a screen-
ing tool for sarcopenia (AUC 0.588) is, therefore, considered insufficient, suggesting that
SARC-F questionnaire is not an adequate tool for sarcopenia screening in patients with SSc. In
our study, SARC-CalF, SARC-F+EBM, and Ishii test proved to be superior to SARC-F alone
for sarcopenia screening, all of them presenting AUC greater than 0.7.
In practical terms, PPV indicates the probability of having sarcopenia when the test is posi-
tive and the NPV, the probability of not having sarcopenia when the test is negative. Generally,
previous studies have indicated higher NPV than PPV for sarcopenia screening tools [4–8]. In
our study, SARC-F presented the lowest PPV and NPV, and SARC-F+EBM the highest PPV
and Ishii test the highest NPV.
In 2016, the (Brazilian) Portuguese-translated version of the SARC-F questionnaire was val-
idated in a population-based study [7]. These authors also proposed to improve its efficacy by
associating SARC-F to calf circumference, as an estimate of muscle mass [7]. The SARC-CalF
significantly improved SARC-F’s screening performance (AUC 0.736 vs. 0.592, p = 0.027),
with a substantial increase in sensitivity (SARC-F 33% vs. SARC-CalF 66%) without
compromising the remaining parameters [7]. In a recent meta-analysis, including 5 studies
(1,127 participants), the pooled results of sensitivity, specificity, and AUC with the EWGSOP
first criteria as the gold standard were 58% (95% CI 46–70), 87% (95% CI 84–90), and 0.860
(95% CI 0.83–0.89), respectively [6]. In our study SARC-CalF also presented a significantly
higher sensitivity, specificity and AUC compared to SARC-F alone in patients with SSc (53%,
84% and 0.718, respectively). Adopting a different approach, Kurita et al proposed to add
“EBM” (“elderly” and “body mass” index information) to SARC-F in order to improve its diag-
nostic accuracy in patients with musculoskeletal disease [5]. Using the EWGSOP2 criteria as
the reference standard, SARC-F+EBM presented higher sensitivity (84.2% vs. 47.4%) and
AUC (0.876 vs. 0.558) than SARC-F alone. Thus, the authors suggested that SARC-F+EBM
may be a better approach to finding cases of sarcopenia in patients with musculoskeletal dis-
ease [5]. In our study, SARC-F+EBM also presented significantly higher sensitivity and AUC
than SARC-F in patients with SSc (60% and 0.832, respectively) and also the best specificity,
+LR and PPV among the other tests evaluated (86%, 4.31, and 45%, respectively). In the
Table 2. Test characteristics and Receiver Operating Curve (ROC) models for the screening tests for identifying sarcopenia (EWGSOP2).
Screening
test



























45.0 (29.2–61.9) 91.9 (85.8–95.5) 4.31 (2.17–8.56) 0.46 (0.25–0.87) 0.832 (0.713–
0.952)




38.2 (28.9–48.4) 96.7 (88.8–99.1) 3.26 (2.15–4.95) 0.18 (0.05–0.66) 0.862 (0.781–
0.944)
� Values are % (95% confidence interval).
¶ p<0.050 by one-way ANOVA among SARC-F, SARC-CalF, SARC-F+EBM and Ishii test.
Abbreviators: AUC: area under the curve; EWGSOP: European Working Group on Sarcopenia in Older People.
https://doi.org/10.1371/journal.pone.0245683.t002
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original validation study of SARC-F+EBM, patients were selected after referral for spinal sur-
gery or knee or hip replacement therapy and osteoarthritis was the most common diagnosis
[5]. Even though SSc patients may present associated osteoarthritis, in the present study severe
functional limitation due to osteoarthritis was not frequent. Considering the specific clinical
features of SSc that may contribute to sarcopenia, such as skin thickening and interstitial lung
disease, we understand that the best performance of SARC-F+EBM in our study is not pre-
dominantly due to similarities with the original study’s population.
Aware of these SARC-F’s limitations, EWGSOP2 consensus mentions that clinicians may
prefer a more formal case-finding tool to be used in populations where sarcopenia is likely [2,
9], suggesting the Ishii screening test as an option in this setting [11]. Applying this method,
the probability of sarcopenia could be easily obtained from a score chart in each sex, combin-
ing three variables—age, grip strength, and calf circumference [11]. When the sum of sensitiv-
ity and specificity was maximized, sensitivity, specificity, and AUC for sarcopenia were 85%,
88%, and 0.939 for men, and 75%, 92%, and 0.909 for women, respectively. In our sample, the
Ishii test also presented the best sensitivity (87%), NPV (96.7%) and–LR (0.182), at the expense
of a small decrease in specificity (73%).
An important aspect to be considered is the choice of the cut-off values for sarcopenia defi-
nition. According to the EWGSOP2 consensus, reference values were provided to increase
harmonization of sarcopenia studies [2]. In a previous regional study, Barbosa-Silva et al. used
a different cut-off for ASMI, since the value recommended by EWGSOP2 consensus was not
able to identify low muscle mass within their sample [28]. In contrast to the study by Barbosa-
Silva et al, the present study, using EWGSOP2 consensus reference values, identified a preva-
lence of sarcopenia similar to those reported in previous studies of SSc patients [13–18]. There-
fore, instead of using the adapted cut-off values, we chose to report our findings using the
reference values recommended by EWGSOP2.
To the best of our knowledge, the present study was the first attempt to evaluate the diag-
nostic accuracy of the SARC-F questionnaire in a sample of patients diagnosed with SSc. As
previously described, our results confirmed the low sensitivity of SARC-F [10] and the better
diagnostic accuracy of other tests compared to SARC-F [5–7, 11, 29–34], but in a different
population with a high reported prevalence of sarcopenia. Therefore, we understand that the
SARC-F+EBM combines the best set of diagnostic properties with the easiest application into
clinical practice since it does not depend on the handgrip strength as Ishii test (dynamometers
are widely available in research centers, but hardly ever present in doctors’ offices). In the con-
text of personalized medicine, the proper choice of a screening strategy using easily applicable
tools could provide relevant diagnostic information about sarcopenia in patients with SSc.
Our study should be interpreted within its limitations. The sample size may not be large
enough to detect some differences in accuracy of the screening tests in some subgroups of
patients, especially among men (only 7 patients) and non-Caucasian (only 17 patients). Also, a
limited sample size could be the reason why there was no difference for most diagnostic mea-
sures among the tests, as only sensitivity and AUC were different between SARC-F and Ishii
test. In addition, due to our cross-sectional design it was not possible to address the direct
impact of a positive screening test in disability, hospitalizations and mortality, as previously
shown in other studies [4, 35, 36]. Moreover, our comprehensive exclusion criteria could
potentially cause selection bias and limit our findings’ external validity. Finally, considering
the clinical features of our sample that may interfere on sarcopenia measures, such as skin
thickening, joint disease, interstitial lung disease and pulmonary hypertension, we acknowl-
edge the limitations of using previously validated tools on a different population and encour-
age the development of specific tests for SSc patients.
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Conclusion
In view of sensitivity, PPV, +LR, -LR, DOR and AUC, SARC-CalF, SARC-F+EBM, and Ishii
test performed better than SARC-F alone as screening tools for sarcopenia in patients with SSc
diagnosed by EWGSOP2 criteria. Only specificity and NPV were greater in SARC-F. Consid-
ering diagnostic accuracy and feasibility aspects, SARC-F+EBM seems to be the most suitable
screening tool to be adopted in routine care of patients with SSc. These findings need valida-
tion in larger samples and different settings, preferably in a longitudinal design to assess the
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